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ABSTRACT 
 
The electrooxidative behaviour of tamoxifen (Tam) and 4-hydroxytamoxifen (TamOH) was investigated by cyclic 
(CV), differential-pulse adsorptive anodic stripping (DPAdAS) and square-wave adsorptive anodic stripping 
(SWAdAS) voltammetric techniques. The anodic oxidation peak of Tamoxifen was attributed to the cyclization 
reaction to form the corresponding phenanthrene derivative and the mechanism of oxidation was postulated on the 
basis of controlled potential electrolysis and isolation of the oxidative product. Oxidative stripping analysis was 
successfully applied to the determination of tamoxifen in a bulk pharmaceutical formulation, and sensitivity in 
human urine and serum was validated. The achieved limits of detection (LOD) of bulk tamoxifen were 1.8 × 10–6 
mol L–1 and 2.4 × 10–6 mol L–1 for DPAdAS and SWAdAS, respectively. The LOD values for tamoxifen in human 
urine and serum sample analysis were 4.75 × 10–7 mol L–1 and 2.63 × 10–7 mol L–1 and 1.98 × 10–7 mol L–1 and 3.28 
× 10–7 mol L–1 for DPAdAS and SWAdAS, respectively. 4-hydroxytamoxifen is oxidised at more positive potentials 
than Tamoxifen, separated from the Tamoxifen stripping peak, and its adsorption to the glassy carbon electrode is 
less pronounced. This affects the ability to determine this important phase I metabolite in serum and urine samples. 
 
Key words: tamoxifen; 4-hydroxytamoxifen; anodic adsorptive stripping voltammetry. 
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INTRODUCTION 
 
Tamoxifen, [Z]-2-[4-(1,2-diphenyl-1-butenyl)-phenoxy]-N,N-dimethylethylamine (Tam), a nonsteroidal anti-
estrogen, has been the most important hormonal agent for treatment of breast cancer for more than two decades, and 
recently has been approved as a long-term chemo preventive agent for breast cancer in healthy women at high risk 
for developing breast cancer.[1-4] Tamoxifen undergoes chemical transformation to its phase I metabolites in vivo, 
resulting in a series of modified species, predominately through methylation or hydroxylation of the benzene rings 
on the tamoxifen structure, to structures such as 4-hydroxytamoxifen.[1] 
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There are a variety of bioanalytical methods that have been developed to determine the concentrations of Tam in 
biological fluids and pharmaceutical preparations. Methods developed for Tamoxifen analysis include capillary 
electrophoresis,[5] and chromatography used in conjunction with a range of detection techniques.[6] Liquid 
chromatography coupled to detection by mass spectrometry is particularly gaining acceptance.[7-8] Electrochemical 
techniques have received significant attention in analysis of pharmaceuticals, due to their low detection limits and 
rapid time frame. They offer the analyst a technique for the analysis of drugs that is rapid, simple and low cost.[9] 
Electrochemical studies of Tamoxifen has centred upon the properties of Tamoxifen by constant current 
potentiometric stripping at a glassy carbon electrode,[10] and voltammetric analysis at a carbon paste electrode [11], 
however due to the importance of the drug there is a desire to have a validated method for rapid determination of 
Tamoxifen in pharmaceutical preparations, and also increase our understanding of the electrochemistry in biological 
fluids not only of Tamoxifen, but of its phase I metabolites.[6] Many organic compounds exhibit surface-active 
properties that are manifested by their adsorption from solution onto the surface of a solid phase.[9] This 
phenomenon forms the basis for adsorptive stripping voltammetry (AdSV), where the species to be determined are 
accumulated on the electrode by adsorption. Adsorptive stripping voltammetry has been demonstrated as a sensitive 
analytical method for a wide range of pharmaceutical compounds that can be adsorbed onto an electrode surface. 
[12-22] The present work is concerned with the validation of the determination of Tamoxifen by adsorptive 
stripping analysis in pharmaceutical formulation and also urine and plasma samples. The electrochemical behaviour 
of a phase I metabolite 4-hydroxytamoxifen (TamOH) is also reported and contrasted to the pure drug. Anodic 
adsorptive stripping analysis is shown to be a dependable technique for determination of tamoxifen. 
 
MATERIALS AND METHODS 
 
All chemicals used were of analytical reagent grade quality and were employed without further purification. Bulk 
form Tamoxifen was obtained from Dabur pharma Ltd. Mumbai, India, and was used as received. Tablets 
containing Tamoxifen citrate (Sensival) labelled 10 mg Tam were purchased from commercial sources. Pure 
samples of Tamoxifen and 4-Hydroxytamoxifen were obtained from Sigma-Aldrich. Britton–Robinson (BR) buffers 
of pH 2–10 (mixtures of 0.04 mol/L acetic, orthophosphoric, and boric acids; adjusted to the required pH with 0.1M 
sodium hydroxide solution or 0.1M hydrochloric acid) were prepared and used as supporting electrolytes with 15 % 
methanol added on pure samples to ensure drug solubility. 
 
For bulk analysis, ten tablets were weighed and the average mass per tablet was determined and then ground to a 
homogeneous fine powder in a mortar. A portion of the finely ground material equivalent to 10 mg of TAM was 
used for analysis. Drug-free human blood, obtained from healthy volunteers was centrifuged (4000 rpm) for 30 
minutes at room temperature, and separated serum samples were stored frozen until assay. An aliquot of serum 
sample was prepared with tamoxifen citrate dissolved in double distilled water to achieve a final concentration of 1 
x 10–3 M. After vortexing for 30 seconds, the mixture was then centrifuged for 10 min. at 4000 rpm in order to 
eliminate serum protein residues. Appropriate volumes of these samples were transferred into the voltammetric cell 
and diluted with Britton Robinson (BR) universal buffer (pH 4.2) and subsequently analyzed according to the 
general analytical procedure. A blank experiment was carried out adopting the above procedure. An aliquot of 
human urine sample was collected and analyzed in the same way as the serum samples. 
 
A CHI model no. 1230 A or 920C electrochemical analyzer (CHI Instruments, USA) was employed for 
electrochemical experiments. A three-electrode cell system was used with a commercial glassy carbon electrode as 
the working electrode, Ag/AgCl (3 M KCl) as the reference electrode, and a platinum wire as the auxiliary electrode. 
Surface pre-concentration steps were performed while stirring at 400 rpm at constant potential as described in the 
text. Bulk electrolysis was performed in the potentiostatic mode using ruthenium oxide (RuO2) doped on Ebonex as 
the working electrode and a Pt wire as the counter electrode. All electrolytes were purged for 10 min with purified 
nitrogen gas, and kept under a blanket of nitrogen. The glassy carbon working electrode was polished to a mirror 
finish using 0.2 um alumina on a felt polishing pad, washed with distilled water, sonicated for 2 minutes in 
methanol, and then dried under a nitrogen purge, before use in stripping experiments. 
 
Typical analytical procedure:- Britton Robinson (BR) universal buffers of pH 4.2 (8.5 ml) plus methanol (1.5 mL) 
and an appropriate small volume aliquot of the drug sample were introduced into the voltammetric cell, through 
which a pure nitrogen stream was passed. An accumulation potential (vs. Ag/AgCl, KCl) was applied at the GCE for 
a selected time period (typically 20 seconds) while the solution was stirred at 400 rpm. At the end of the 
accumulation time period, the stirring was stopped and 10 s were allowed for the solution to become quiescent. 
Then, the voltammograms were recorded by scanning the potential toward the positive direction using the cyclic 
voltammetric (CV), differential pulse (DP) or square wave (SWV) waveform. All data was obtained at room 
temperature. The conditions used in this paper, which were shown to give well resolved peaks that are later 
validated are for DPAdAS; scan rate ν (10 mV s-1), pulse height a (5 to 50 mV), pre-concentration potential 
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(Eacc=0.8) and pre-concentration time (tacc 20 sec.), SWAdAS; pre-concentration potential (Eacc=0.8), pre-
concentration time (tacc 20 sec.), pulse-height a (5 to 50 mV), frequency f (40 Hz) and scan increment ∆Es (10 mV). 
 
RESULTS AND DISCUSSION 
 
Voltammetry 
For all the electrochemical methods employed, Tam gave one well-defined oxidation peak in Britton Robinson (BR) 
universal buffer (pH 4.2):15 % methanol at glassy carbon. Cyclic voltammograms for Tam were recorded at 
different pH, scan rate and concentration values. The effect of pH value on the oxidation peak current of TAM was 
examined in the range of pH 2-10 in Britton Robinson (BR) universal buffer using a test concentration of 1x10-4 mol 
L-1 tamoxifen. The maximum peak height was seen at pH 4.2, leading to the choice of this pH for the analytical 
experiments. Pre-concentration times of between 10 and 120 seconds indicated that a maximum peak current was 
obtained after 20 seconds at 0.8 V vs Ag/AgCl, representing a significantly higher peak than studies involving no 
pre-concentration, and this was chosen as the standard conditions in all subsequent voltammetric studies where only 
Tam is present. Figure 1 shows the voltammogram at different scan rates after pre-concentration (with an inset of the 
effect of pH on peak height). The peak potentials are shifted to more positive values, as expected for an irreversible 
process with a contribution from diffusion control.  
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Figure1. Voltammogram of 1 x 10-4 M Tamoxifen at scan rates of 100 (A), 200 (B), 300 (C),  400 (D) and 500 (E) mV/s at pH 4.2. Inset 
plot of ip vs pH for 50 mV/s scan rate 
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Figure 2. Differential pulse (DPAdAS) and the square wave voltammogram (SWAdAS) of 1 x 10-4 M Tamoxifen, pH 4.2 BRB. 
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Analysis of the peak height (ip) with increasing scan rate indicates that the height of the oxidation peak ip is not 
directly proportional to v over the scan rates 50 to 500 mV/s, with deviations from linearity also observed for a plot 
of ip with v1/2, confirming that adsorptive stripping is a major contribution to peak current, in addition to some 
diffusive contribution. Successive scans lead to a significant decrease in peak height (ip). The voltammogram shows 
the linear dependence of peak height with concentration. In order to obtain the best level of detection for the 
Tamoxifen, differential pulse and square wave voltammetry were undertaken, once again using the same conditions 
of pre-concentration used for the linear voltammetry. Figure 2 shows both the Square wave and differential pulse 
anodic adsorptive voltammograms (SWAdAS and DPAdAS) for the pre-adsorbed Tam.  
 
In all cases a single oxidative peak is observed. These conditions were applied firstly to pharmaceutical bulk 
formulation to determine the quality of the analysis possible. 
 
Validation of the Procedure 
Validation of the proposed procedure for assay of the drug at trace levels was examined via evaluation of the limit of 
detection (LOD), limit of quantization (LOQ), reproducibility, recovery, selectivity, robustness and ruggedness. The 
Limits of detection (LOD) and quantification (LOQ) of Tam were calculated using the following equations: 
 
LOD= 3s/b 
 
LOQ=10s/b 
 
s is the standard deviation of the intercept and b is the slope of the calibration curve. Reproducibility, accuracy and 
precision of results applying the described stripping voltammetric methods were examined by performing five 
replicate analysis of standard solutions of Tam. The mean percentage recovery (%R) had been calculated for the 
found concentrations as a percent of the nominal concentrations in the standard solutions. Accuracy was expressed 
as relative error (RE %) while precision was assessed from the relative standard deviation in percentage (RSD %) of 
the mean recovery. The obtained results confirmed the reliability of the described stripping voltammetric methods. 
The robustness was examined by evaluating the influence of small variations on some of the most important 
procedure variables including pre-concentration potential (Eacc) and pre-concentration time (tacc). The obtained result 
provided an indication of the reliability of the proposed procedure for the assay of TAM, and hence it can be 
considered robust. The obtained mean percentage recoveries based on the average of five replicate measurements 
were not significantly affected within the studied range of variations of some operational parameters, and 
consequently the proposed procedure can be considered robust. The ruggedness test of the analytical assay method is 
defined as the degree of reproducibility of assay results obtained by the successful applications of the assay over 
time and multiple laboratories and analysts. Two analysts analyzed the same standard with SWAdAS and DPAdAS 
methods using the same instrument. The methods were found to be rugged with the results of variation coefficients 
for SWAdAS and DPAdAS methods for first and second analysts, respectively. The results show no statistical 
differences between different analyses. 
 
Table I. Stripping voltammetric determination of Tamoxifen urine using SWAdAS and DPAdAS modes. 
 
Techniques SWAdAS DPAdAS 
Linearity  range  (mol cm-3) 0.2x10-6– 1.5x10-6 0.2x10-6– 1.5x10-6 
Slope (µA/M) 3.5x10-6 1.68x10-6 
Intercept (µA) 0.43 0.16 
Correlation coefficient 0.996 0.999 
t- test 0.29 0.27 
Variance ratio (F) 1.08 1.06 
LOD (M) 1.98x10-7 4.75x10-7 
LOQ (M) 6.54x10-7 1.3x10-8 
Repeatability of 
peak current (RSD%)  
0.74 0.62 
Repeatability of 
peak potential (RSD%) 
0.19 0.20 
Reproducibility of 
peak current (RSD%) 
0.71 0.68 
Reproducibility of 
peak potential (RSD%) 
0.11 0.15 
 
 
Assay of Tam in spiked human urine 
Tamoxifen in spiked human urine was successfully analyzed by both DPAdAS and SWAdAS without the necessity 
for extraction of the drug prior to the analysis. Representative DPAdAS and SWAdAS voltammograms of Tam in 
spiked human urine recorded under the optimum operational conditions of the described stripping voltammetric 
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methods are shown in Figure 4. No major interfering peaks for Tam were observed in the blank human urine within 
the studied potential range.  Linear variations of the peak current (ipa) with concentration of TAM in spiked human 
urine were obtained within the concentration ranges of  0.2×10–6  to 1.5×10–6  mol L-1 (DPAdAS) and 0.2×10–6  to 
1.5×10–6  mol L-1 (SWAdAS) following the regression equations:  (ipa (µA) = 41.80 C (µmol L–1) + 0.466; r = 0.994 
and n = 6 ), and (ipa (µA) = 55.5 C (µ mol L-1) + 0.169; r = 0.999 and n =6), respectively. Detection limits of 
4.75×10–7 and 1.98×10–7 mol L-1 and quantitation limits of 1.3×10–8 and 6.54×10–7 mol L-1 TAM were thus achieved 
by the DPAdAS and SWAdAS methods respectively. Mean percentage recoveries and relative standard deviations 
of 101.14 ± 2.38 (DP-AAdSV) and 101.16 ± 1.91 (SW-AAdSV) were achieved based on replicate measurements of 
5×10–6 mol L-1 (Tables I and II) TAM in spiked human urine. These results confirmed the reliability of the described 
stripping voltammetric methods for assay of Tam in human urine. 
 
Table II. Application of the stripping voltammetric determination of Tamoxifen in urine using SWAdAS and DPAdAS modes. 
 
Techniques SWAdAS DPAdAS 
Added (µġ cm-3) 
0.2 
0.35 
0.5 
0.75 
0.9 
1.5 
0.2 
0.35 
0.5 
0.75 
0.9 
1.5 
Found (µġ cm-3) 
0.21 
0.351 
0.499 
0.751 
0.91 
1.51 
0.212 
0.352 
0.498 
0.751 
0.899 
1.51 
n 6 6 
Average 
recovery % 
105.00 
100.28 
099.80 
100.13 
101.11 
100.66 
106.00 
100.57 
099.60 
100.13 
099.88 
100.66 
Mean 
S.D 
RSD % 
101.16 
1.93 
1.91 
101.14 
2.41 
2.38 
Bias % -0.16 -0.14 
 
Assay of Tam in spiked human serum 
Tamoxifen in spiked human serum was successfully analyzed by DPAdAS and SWAdAS without the necessity for 
extraction of the drug prior to analysis. Representative DPAdAS and SWAdAS voltammograms of tamoxifen in 
spiked human serum are shown in Figure 3. No significant interfering peaks for Tam were observed in the blank 
human serum within the studied potential range.   
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Figure 3. DPAdAS (top) and SWAdAS (bottom) of Tam in blood sample at spiked concentrations of 5.0 x 10-7 M (A), 8.0 x 10-7 M (B) and 
1.0 x 10-6 M (C). ; Eacc.=0.8 V, tacc.=20 s, pulse amplitude 50 mV, pulse width 30 ms, ∆E=10 mV and BR buffer of pH 4.2. 
 
Linear variations of the peak current (ipa) with concentration of TAM in spiked human serum were obtained within 
the concentration ranges of  0.3×10–6  to 1×10–6  mol L-1 (DPAdAS) and 0.3×10–6  to 1×10–6 mol L-1 (SWAdAS) 
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following the regression equations:  (ipa (µA) = 41.80 C (µ mol L-1) + 0.466; r = 0.998 and n = 8 ), and (ipa (µA) = 
55.5 C (µ mol L-1) + 0.169; r = 0.998 and n = 8), respectively. Detection limits of 2.63×10–7and 3.2×10–7 mol L-1 and 
quantitation limits of 8.6×10–7  and 1×10–8  mol L-1  for Tam were achieved by the DPAdAS and SWAdAS methods 
respectively. Mean percentage recoveries and relative standard deviations of 100.33 ± 0.556 (DP-AAdSV) and 
101.68 ± 2.07 (SW-AAdSV) were achieved based on replicate measurements of 1×10–6 mol L-1 (Tables III and IV) 
tamoxifen in spiked human serum. These results confirmed the reliability of the described stripping voltammetric 
methods for assay of TAM in human serum. 
 
Table III. Stripping voltammetric determination of Tamoxifen serum using SWAdAS and DPAdAS modes. 
 
Techniques SWAdAS DPAdAS 
Linearity  range (mol cm-3) 0.3x10-6 – 1x10-6 0.3x10-6 – 1x10-6 
Slope (µA/M) 1.98x10-6 2.4x10-6 
Intercept (µA) 0.14 0.43 
Correlation coefficient 0.998 0.998 
t-test 0.37 0.31 
Variance ratio (F) 1.20 1.13 
LOD (M) 3.28x10-7 2.63x10-7 
LOQ (M) 1x10-8 8.6x10-7 
Repeatability of 
peak current (RSD%) 0.62 0.77 
Repeatability of 
peak potential (RSD%) 0.16 0.18 
Reproducibility of 
peak current (RSD%) 0.54 0.59 
Reproducibility of 
peak potential (RSD%) 0.12 0.17 
 
Table IV. Application of the stripping voltammetric determination of Tamoxifen in serum using SWAdAS and DPAdAS modes. 
 
Techniques SWAdAS DPAdAS 
Added (µġ cm-3) 
0.3 
0.4 
0.5 
0.6 
0.7 
0.8 
0.9 
1 
0.3 
0.4 
0.5 
0.6 
0.7 
0.8 
0.9 
1 
Found (µġ cm-3) 
0.31 
0.42 
0.499 
0.601 
0.698 
0.81 
0.902 
1.04 
0.302 
0.398 
0.501 
0.599 
0.701 
0.802 
0.91 
1.01 
n 8 8 
Average 
recovery % 
103.33 
105.00 
99.80 
100.16 
099.71 
101.25 
100.22 
104.00 
100.66 
099.50 
100.20 
099.83 
100.14 
100.25 
101.11 
101.00 
Mean 
S.D 
RSD % 
101.68 
2.11 
2.07 
100.33 
0.556 
0.554 
Bias % -0.68 -0.33 
 
Controlled potential Electrolysis Behavior (CPE) 
Controlled potential electrolysis was carried out at -1.12 V on a ruthenium oxide (RuO2) doped on Ebonex electrode 
in 0.04 M Britton Robinson (BR) universal buffer (pH 4.2). Literature reports have identified that the following 
reaction occurs in compounds of a similar structure.[10, 23] 
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(Scheme-1) 
 
During electrolysis, it was confirmed that 2 electrons were consumed for each mole of tamoxifen dissolved in 
solution, confirming a two electron process. After electrolysis, the catholyte was cooled to 278 – 283K in ice and 
neutralized with sodium hydroxide solution. This solution was then filtered, and the filtrate was treated with diethyl 
ether to extract the highly viscous white product. The IR spectrum showed a sharp spike at 3050 cm-1, characteristic 
of the cyclisation to form the phenanthrene, with the disappearance of the peak at 1600 cm-1 corresponding to the 
C=C stretch in the original Tamoxifen compound.  
 
Electrochemical behaviour of 4-Hydroxytamoxifen 
An important phase I metabolite for Tam is 4-hydroxytamoxifen (TamOH), and as it is important to understand the 
stripping behaviour of this copound. Figure 6 shows the SWAdAS and DPAdAS of a mixture of pure Tam and 
TamOH in pH 4.2 BRB buffer after an accumulation potential of 0.4 V vs Ag/AgCl (20 s). The curves show that the 
adsorbed TamOH is oxidised at a more positive potential than the Tam. As such, in analyses of urine and plasma 
samples where phase I metabolites would be present, the peak used for validation would only include the Tam drug. 
The adsorption of TamOH to the surface of glassy carbon is less pronounced than Tam, as seen by the lower 
stripping peak for TamOH relative to Tam, and this affects its determination in urine and plasma samples. The 
presence of TamOH in comparable quantities to Tam would be able to be observed in urine and plasma samples at a 
potential of 0.5-0.6 V vs Ag/AgCl, however its limited adsorption and presence of interfering species in this region 
has limited a validated technique being established in this study. 
 
CONCLUSION 
 
The electrochemical investigation of Tam at the glassy carbon electrode and ruthenium oxide (RuO2) doped on 
Ebonex electrode in phosphate buffered solution has been studied, based on the adsorption behavior of TAM at the 
glassy carbon electrode surface. The Cyclic voltammetric behavior show well defined irreversible anodic peak at 
1.12V, so to the cyclization reaction to form the corresponding phenanthrene derivative. A fully validated, simple, 
sensitive, selective, fast and low-cost differential pulse and square wave adsorptive anodic stripping voltammetric 
methods were developed for determination of Tam in bulk form, and in spiked human urine and serum. The 
described methods could be recommended for use in trace analysis, quality control and clinical laboratories. The 
phase I metabolite TamOH was shown to be significantly separated from Tamoxifen, being oxidised at a lower 
potential, but its lower adsorptive character and interfering species at ots stripping potential limits our ability to 
validate a method for its determination. 
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